神经胶质瘤是成人最常见的原发性恶性脑瘤，约占脑和中枢神经系统肿瘤的80％。2021年世界卫生组织（WHO）根据其组织学特征和分子改变，对神经胶质瘤进行了新的分类法。异柠檬酸脱氢酶（IDH）在细胞能量生成中起着关键作用，催化异柠檬酸的脱羧反应。 IDH基因的突变会干扰细胞分化，并作为可以用于分类神经胶质瘤的分子生物标志物。例如，突变的IDH广泛检测于低级别的神经胶质瘤，而野生型则检测于高级别的神经胶质瘤，包括胶质母细胞瘤。长链非编码RNA（lncRNA）参与表观遗传的基因表达，并对神经胶质瘤发生发展有贡献。为研究lncRNA在生物标志物中的潜在作用，我们研究了IDH基因突变状态下lncRNA的失控情况。我们发现，几种lncRNA，即AL606760.2，H19，MALAT1，PVT1和SBF2-AS1可能被用作神经胶质瘤的风险因素，而AC068643.1，AC079228.1，DGCR5，FAM13A-AS1，HAR1A和WDFY3-AS2则可能具有保护作用。值得注意的是，H19，MALAT1，PVT1和SBF2-AS1已与耐替莫唑胺的神经胶质瘤患者相关联。这项综述研究表明，针对与神经胶质瘤相关的lncRNA可能有助于神经胶质瘤的治疗。© 2023作者。由Informa UK有限公司（Taylor＆Francis集团）出版。

Glioma is the most common primary malignant brain tumor in adults and accounts for approximately 80% of brain and central nervous system tumors. In 2021, the World Health Organization (WHO) published a new taxonomy for glioma based on its histological features and molecular alterations. Isocitrate dehydrogenase (IDH) catalyzes the decarboxylation of isocitrate, a critical metabolic reaction in energy generation in cells. Mutations in the IDH genes interrupt cell differentiation and serve as molecular biomarkers that can be used to classify gliomas. For example, the mutant IDH is widely detected in low-grade gliomas, whereas the wild type is in high-grade ones, including glioblastomas. Long non-coding RNAs (lncRNAs) are epigenetically involved in gene expression and contribute to glioma development. To investigate the potential use of lncRNAs as biomarkers, we examined lncRNA dysregulation dependent on the IDH mutation status. We found that several lncRNAs, namely, AL606760.2, H19, MALAT1, PVT1 and SBF2-AS1 may function as glioma risk factors, whereas AC068643.1, AC079228.1, DGCR5, FAM13A-AS1, HAR1A and WDFY3-AS2 may have protective effects. Notably, H19, MALAT1, PVT1, and SBF2-AS1 have been associated with temozolomide resistance in glioma patients. This review study suggests that targeting glioma-associated lncRNAs might aid the treatment of glioma.© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.